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ttp://dx.doi.org/10.1016/j.ajpath.2014.11.0205-a Reductase type 2 (SRD5A2) is a critical enzyme for prostatic development and growth. Inhibition of
SRD5A2 by ﬁnasteride is used commonly for the management of urinary obstruction caused by benign
prostatic hyperplasia. Contrary to common belief, we have found that expression of SRD5A2 is variable
and absent in one third of benign adult prostates. In human samples, absent SRD5A2 expression
is associated with hypermethylation of the SRD5A2 promoter, and in vitro SRD5A2 promoter activity
is suppressed by methylation. We show that methylation of SRD5A2 is regulated by DNA
methyltransferase 1, and inﬂammatory mediators such as tumor necrosis factor a, NF-kB, and IL-6
regulate DNA methyltransferase 1 expression and thereby affect SRD5A2 promoter methylation and
gene expression. Furthermore, we show that increasing age in mice and humans is associated with
increased methylation of the SRD5A2 promoter and concomitantly decreased protein expression.
Artiﬁcial induction of inﬂammation in prostate primary epithelial cells leads to hypermethylation of the
SRD5A2 promoter and silencing of SRD5A2, whereas inhibition with tumor necrosis factor a inhibitor
reactivates SRD5A2 expression. Therefore, expression of SRD5A2 is not static and ubiquitous in benign
adult prostate tissues. Methylation and expression of SRD5A2 may be used as a gene signature to tailor
therapies for more effective treatment of prostatic diseases. (Am J Pathol 2015, 185: 870e882; http://
dx.doi.org/10.1016/j.ajpath.2014.11.020)Supported by the NIH/National Institute for Diabetes and Digestive and
Kidney Diseases (NIH/R01 DK091353).
Disclosures: None declared.Benign prostatic hyperplasia (BPH) is a global health
problem that affects more than 90% of men older than age
80.1 Progressive enlargement of the prostate gland, the
only solid organ that grows during adulthood, has been
linked to bladder outlet obstruction with associated
obstructive and irritating lower urinary tract symptoms
that can impact an individual’s quality of life and, in
severe cases, lead to irreversible bladder dysfunction and
renal failure as a result of inadequate urine emptying.1
Signiﬁcant strides have been made in the medical man-
agement of BPH and its associated symptoms using alpha
blockers and/or 5-a reductase inhibitors. Selective alpha
blockers inhibit the noradrenergic receptors of the lower
urinary tract to relax the bladder neck/prostatic urethral
smooth muscle cells and improve urinary outﬂow. 5-a
Reductase (SRD5A2) inhibitors block conversion of
testosterone to dihydrotestosterone by the enzyme
SRD5A2 in the prostate and pelvic tissue, leading tostigative Pathology.
.systemic reduction of this potent androgen and a progressive
decrease in prostate volume. The SRD5A2 inhibitor ﬁnas-
teride has been shown in several large clinical trials to reduce
prostate size by 20%, improve urinary ﬂow rate, and
improve urinary bothersome symptom scores in men
suffering from bladder outlet obstruction caused by BPH.2e5
Despite their widespread use and clinical effectiveness, 25%
to 30% of patients are resistant to the therapeutic effects of
5-a reductase inhibitors and another 5% to 7% of patients
develop worsening symptoms and ultimately may require
surgery.5,6
Contrary to the common belief that SRD5A2 is expressed
ubiquitously in benign adult prostate tissue, we have found
that expression of SRD5A2 is variable and absent in 30% of
DNMT Reduces SRD5A2 in Adult Prostateadult human prostate tissues.6 We have shown that the
SRD5A2 gene contains a promoter with a rich CpG island
capable of being methylated.6 Because epigenetic factors
can regulate the expression of genes,7 we hypothesized that
methylation of SRD5A2 leads to reduced SRD5A2 gene
expression and protein production during adulthood in
benign prostatic tissues. We show that members of the DNA
methyltransferase (DNMT) family regulate methylation of
SRD5A2. The three DNMTs, DNMT1, DNMT3a, and
DNMT3b,8,9 can be classiﬁed as de novo methyltransferases
that are able to both methylate previously unmethylated
CpG islands and maintain methylated genomic information
by copying pre-existing methylated nucleotide sites into
new DNA strands during replication.10,11 Speciﬁcally, we
show that DNMT1, and not DNMT3a or DNMT3b, regu-
lates methylation of the SRD5A2 gene promoter. This
epigenetic modiﬁcation generally functions to repress gene
expression and is important for the regulation of cellular
differentiation and development.12
Because inﬂammatory changes have been associated with
the diagnosis of BPH13 as well as increasing age,14 we
investigated and found that tumor necrosis factor a (TNF-a),
NF-kB, and IL-6 regulate DNMT1 and subsequent methyl-
ation of the SRD5A2 promoter region. In addition, we show
that SRD5A2 promoter methylation and reduced protein
expression are associated closely with increasing age in both
human and mouse tissues.
Materials and Methods
Patients
After obtaining institutional review board approval, a total of
96 benign human prostate samples from consecutive tran-
surethral resections of the prostate were included in this
study. Patients’ ages ranged from 52 to 91 years old (average
age, 71 years). All patients underwent transurethral resection
of the prostate for symptoms of bladder outlet obstruction
secondary to BPH. Prostatic samples were parafﬁn-
embedded and histologically evaluated by a genitourinary
pathologist (C.-L.W.). Parafﬁn-embedded samples were used
for immunohistochemical analysis, whereas fresh-frozen
samples were used for methylation pull-down assays.
Cell Culture and Transfection
Human BPH-1 cells that were immortalized with Simian virus
40 large T-antigen cells were provided by Dr. Simon Hayward
(Vanderbilt University, Nashville, TN). They were cultured in
Dulbecco’s modiﬁed Eagle’s medium (5% fetal calf serum).
Benign prostate epithelial cells were obtained from Lonza
(Basel, Switzerland), and were maintained in the tissue culture
medium provided by the manufacturer. The BPH-1/p65 cells
were established using 1 mg/mL G418 (Invitrogen, Grand
Island,NY) after transfectionofwild-typep65 expressionvector
or control empty vector. Transfection of plasmid and the siRNAThe American Journal of Pathology - ajp.amjpathol.orgwere performed using Fugene 6 or XtremeGENE according to
the manufacturer’s instructions (Roche, San Francisco, CA).
Reagents and Luciferase Assay
Antibodies to SRD5A2 (ab101896; Abcam, Cambridge,
MA), DNMT1 (sc-20701; Santa Cruz Biotechnology, Santa
Cruz, TX), DNMT3a (sc-20703; Santa Cruz Biotech-
nology), DNMT3b (sc-20704; Santa Cruz Biotechnology),
TNFR1 (3736; Cell Signaling Technology, Danvers, MA),
glyceraldehyde-3-phosphate dehydrogenase (2118; Cell
Signaling Technology), p65 (4764; Cell Signaling Tech-
nology), IL-6 (MAB206; R&D Systems, Minneapolis, MN),
p-STAT3 (9131; Cell Signaling Technology) and STAT3
(12640; Cell Signaling Technology), prostatic acid phos-
phatase (ab108984; Abcam), and normal rabbit IgG (2729;
Cell Signaling Technology) were purchased. Lipopolysac-
charides (LPS) were purchased from Sigma (St. Louis,
MO). Recombinant human TNF-a and recombinant human
IL-6 were purchased from R&D. DNMT1 siRNA (M-
004605-01-0005), DNMT3a siRNA (M-006672-03-0005),
DNMT3b (M-006395-01-0005), and Non-Targeting siRNA
#1 (D-001210-01-05) were purchased from Dharmacon
(Pittsburgh, PA); TNFR1 siRNA (sc-29507) was purchased
from Santa Cruz; and NF-kB p65 siRNA II was purchased
from Cell Signaling (6534). IL-6 cDNA was purchased from
Origene (Rockville, MD); human DNMT1 cDNA was
purchased from Genecopoeia (Rockville, MD); and
pcDNA1-p65/Rel A was a gift from Abdalla Jama (Kar-
olinska Institute, Sweden). The pSV40-Renilla luciferase
expression plasmid was purchased from Promega (Madison,
WI). At 48 hours after transfection with the appropriate
plasmids, cells were lysed and luciferase activity was
measured in a Synergy Luminescence Microplate Reader
(BioTek, Winooski, VT) using the Dual-Luciferase Reporter
Assay System (Promega). TNF receptor (TNFR) inhibitor
was a gift from Amgen (Thousand Oaks, CA).
Immunohistochemistry
Immunohistochemistry was completed as previously
described.6 Brieﬂy, tissue sections were incubated with the
SRD5A2 primary antibody (ab101896, ABCAM ) at a
concentration of 1/200. The secondary antibody was used at
a concentration of 1/300. For assessment of immunoreac-
tivity to the SRD5A2 antibody, three representative areas at
a magniﬁcation of 40 were selected for each sample, and
500 cells were counted manually from each representative
section. The immunohistochemical reactivity was deﬁned as
follows: <10%, 11% to 30%, 31% to 60%, and >60%
signiﬁed negative, weak, medium, or strong staining,
respectively. Based on our previous experience6 and newly
performed statistical analysis, the most natural breakpoint
for SRD5A2 analysis was samples with less than 10%
immunoreactivity and those with greater than 10% immu-
noreactivity. Therefore, the samples were scored as negative871
Ge et alif they were less than 10% immunoreactive and as positive
if they were greater than 10% immunoreactive.
Animals
Benign prostatic tissues were harvested from C57BL/6 male
mice at different ages (3, 6, and 12 months; n Z 6 per
group). The mice were housed and maintained in laminar
ﬂow cabinets under speciﬁc pathogen-free conditions. All
animal experiments were approved by the Institutional
Animal Care and Use Committee at Massachusetts General
Hospital and were performed in accordance with ethical
guidelines.
DNA Extraction and Methylation Detection
DNA was extracted from cell lines, human prostate tissues,
or murine prostates with QIAamp DNA Kits (Qiagen,
Valencia, CA). Methylated CpG islands were detected by
the MethylCollector Ultra kit (Active Motif, Carlsbad, CA).
The primers used for PCR were as follows: SRD5A2:
50-GCATCCTTGAGAAAGGGGTA-30 (forward), and 50-
CTCTGCTGGCACTGAACCT-30 (reverse). The PCR
products were subjected to electrophoresis on 1% agarose
gels, and the signal was visualized with Fluor-S Multi-
Imager (Bio-Rad, Hercules, CA). Quantitative data were
obtained using Quantity One software version 4.6.9 (Bio-
Rad). Real-time PCR was performed using the Power
SYBR Green RNA-to-CT 1-Step Kit and performed on a
7300 Real-Time PCR System (Applied Biosystems, Wal-
tham, MA) according to the manufacturer’s instructions.
The reaction for each sample was performed in triplicate.
Treatment of BPH-1 Cells with 5-Aza-20-Deoxycytidine
Human BPH-1 cells were treated with 10 mmol/L 5-aza-20-
deoxycytidine (Sigma) for 48 hours. A fresh medium con-
taining 5-aza-20-deoxycytidine was added every 24 hours.
Chromatin Immunoprecipitation Assay
A chromatin immunoprecipitation assay was performed
using the SimpleChIP enzymatic chromatin IP kit (Cell
Signaling) as described previously.15 The primers for the
DNMT1-binding sequence on the SRD5A2 promoter were
as follows: 50-GCATCCTTGAGAAAGGGGTA-30 (for-
ward), and 50-CTCTGCTGGCACTGAACCT-30 (reverse).
In Vitro Methylation
SRD5A2 promoter-luciferase constructs (1 mg) were
methylated in vitro by M.SssI (New England Biolabs,
Ipswich, MA) as recommended by the manufacturer.
Brieﬂy, plasmids were incubated with the M.Sssi (1 unit/
mg DNA) in the presence of 1 Buffer 2 (New England
Biolabs, Ipswich, MA) and 160 mmol/L SAM at 37C for 4872hours. M.SssI was heat-inactivated at 65C for 20 mi-
nutes, and removed by a PCR puriﬁcation kit (Qiagen).
Global Methylation
The global CpG methylation measurement in BPH-1 cells
and murine prostates was performed using the colorimetric
method of the MethylFlash Methylated DNA quantiﬁcation
Kit (Epigentek, Farmingdale, NY) according to the manu-
facturer’s instructions.
DNMT1 Activity Assay
Epigentek was used to determine the DNMT1 enzymatic
activities according to the manufacturer’s manual. Nuclear
protein was extracted from BPH-1 cells and human BPH
samples using the NE-PER Nuclear and Cytoplasmic
Extraction Kit (Pierce, Rockford, IL) and used as the
source for DNMT1 activity.
Cytokine Assay
Cytokine productions were analyzed with a Milliplex Map Kit
for the human cytokine assay (Millipore, Billerica, MA) ac-
cording to the manufacturer’s instructions, which allowed the
simultaneous quantiﬁcation of the following cytokines:
epidermal growth factor, granulocyte colony-stimulating factor,
granulocyte macrophage colony-stimulating factor, interferon-
a2, interferon-g, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15,
IL-17, IL-1Ra, IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7,
IL-8, interferon-geinduced protein 10, monocyte chemotactic
protein 1, macrophage inﬂammatory protein-1a, macrophage
inﬂammatory protein-1b, regulated on activation normal T-cell
expressed and secreted, TNF-a, TNF-b, and vascular endo-
thelial growth factor.
Statistical Analysis
Descriptive statistics were presented as means  SD.
Patients were divided into two groups based on a positive or
negative methylation status or protein expression of
SRD5A2, and descriptive analyses comparing clinical in-
formation were performed. Statistical analyses were per-
formed with JMP Pro version 11 (SAS Institute, Inc., Cary,
NC). Continuous variables were expressed as means  SD
and assessed using the Student’s t-test, whereas the c2 test
or the Fisher exact test were performed for categoric vari-
ables. All tests were two-tailed, and P < 0.05 was
considered statistically signiﬁcant.
Results
Methylation of the SRD5A2 Promoter Correlates with
SRD5A2 Protein Expression in BPH Samples
Previously, we showed that normal prostate samples have
signiﬁcant variability in protein expression of SRD5A2, withajp.amjpathol.org - The American Journal of Pathology
Figure 1 Methylation status of SRD5A2 promoter correlates with SRD5A2 protein expression in benign prostatic hyperplasia samples. A: Representative ﬁgures
for immunohistochemical analysis of benign prostatic hyperplasia samples. The immunohistochemistry was deﬁned as follows: <10% and >10% were deﬁned as
negative and positive, respectively. B: Representative ﬁgures for SRD5A2 protein expression by immunoblot and methylation status of SRD5A2 promoter by
methylation pull-down assay. Original magniﬁcation, 400 (A). GAPDH, glyceraldehyde-3-phosphate dehydrogenase; WB, Western blot.
DNMT Reduces SRD5A2 in Adult Prostateapproximately 30% showing minimal or no expression of the
protein.6 We showed the presence of a CpG island in the
promoter region of SRD5A2, and that methylation of the
promoter region in 18 benign prostate samples (obtained
from patients undergoing a radical prostatectomy for the
management of prostate cancer) was associated strongly with
reduced expression of SRD5A2.6 Here, we expanded our
ﬁndings to a larger cohort with 96 patients with samples
obtained from patients undergoing transurethral resection of
the prostate for BPH, a nonmalignant prostatic disease.
Similar to our previous ﬁndings, we found that 35 of 96
(36.5%) patients did not express the SRD5A2 protein and had
methylated CpG promoter regions. Conversely, we found that
in 39 of 96 (40.6%) patients, decreased methylation of the
SRD5A2 promoter was associated with expression of the
SRD5A2 protein, suggesting a strong association between
methylation of the SRD5A2 promoter and absence of
SRD5A2 protein expression (P < 0.0001, Fisher exact test)
(Figure 1 and Table 1). However, we also found that 10 of 96
(10.4%) patients did not express SRD5A2 while the promoter
was hypomethylated, suggesting that alternative mechanisms,
besides methylation of the promoter region, may act to
regulate expression of SRD5A2 (Table 1). Prostatic acid
phosphatase immunostaining was used as a positive control,
and was expressed uniformly in all prostate samples, irre-
spective of SRD5A2 expression levels (Figure 1A).Table 1 Methylation Status of the SRD5A2 Promoter Correlates
with SRD5A2 Protein Expression in BPH Samples
Protein expression
Methylated
SRD5A2
Unmethylated
SRD5A2 Total
SRD5A2 expression
negative
35 (36.5%) 10 (10.4%) 45 (46.9%)
SRD5A2 expression
positive
12 (12.5%) 39 (40.6%) 51 (53.1%)
47 (49.0%) 49 (51.0%)
A total of 96 human benign prostatic samples from transurethral resec-
tion of the prostate were included in this study (P < 0.0001). All tests were
two-tailed, and P < 0.05 was considered statistically signiﬁcant.Methylation of the SRD5A2 Promoter Is Regulated by
DNMT1
To better understand the mechanistic pathways that may regu-
late the methylation and expression of SRD5A2, we evaluated
theDNMT family of genes that have been known to regulate the
methylation and expression of various genes that are important
in benign and malignant diseases.16,17 As a ﬁrst step, we
randomly selected 12 samples from the SRD5A2 methylated
group and 13 samples from the unmethylated group (Table 1),
and then we evaluated the immunohistochemical protein ex-
pressions for DNMT1, DNMT3a, and DNMT3b. We foundThe American Journal of Pathology - ajp.amjpathol.orgthat there was no correlation between protein expression of
DNMT3a and DNMT3b and the methylation status of the
SRD5A2 promoter region (data not shown). In contrast, we
found that 10 of 12 (83%) prostate samples expressed DNMT1
in the methylated group, and 9 of 13 (69%) did not express
DNMT1 in the unmethylated group (PZ 0.015), indicating a
statistically signiﬁcant correlation between methylation of the
SRD5A2 promoter and the expression of DNMT1 as assessed
by immunohistochemistry as well as Western blot analysis
(Figure 2A and Table 2). We also conﬁrmed that DNMT1 ac-
tivitywas consistent with protein expression levels (Figure 2B).
Next, we evaluated the expression of DNMT1 and
methylation of SRD5A2 in vitro. BPH-1 cells, which do not
express the SRD5A2 gene and are methylated at the SRD5A2
promoter,6 were treated with the demethylating compound 5-
aza-20-deoxycytidine. We found that at baseline, DNMT1 was
expressed in BPH-1 cells, however, on exposure to 5-aza-20-
deoxycytidine, there was a signiﬁcant reduction in DNMT1
levels that was accompanied by increased SRD5A2 expression,
whereas there was no change in the levels of DNMT3a or
DNMT3b. In a similar fashion, suppression of DNMT1 by
siRNA reduced DNMT1 dramatically and led to re-expression
of SRD5A2 (Figure 2C). To further conﬁrm that methylation of
the SRD5A2 promoter was regulated by DNMT1 rather than
DNMT3a or DNMT3b, we transfected DNMT1, DNMT3a,
and DNMT3b siRNA into BPH-1 cells, and found that only
silencing of DNMT1 reactivated the expression of SRD5A2873
Figure 2 Methylation of the SRD5A2 promoter is regulated by DNMT1. A: A representative ﬁgure for DNMT1 protein expression by immunoblot. B: DNMT1 activity
assay. C: Benign prostatic hyperplasia (BPH)-1 cells were treated with 5-AZC or DNMT1 siRNA for 48 hours, and then cells were harvested for immunoblot analysis. D:
BPH-1 cells were transfected with DNMT1, DNMT3a, or DNMT3b siRNA, and then cells were harvested for immunoblot analysis. E: SRD5A2 promoter-luciferase constructs
were methylated in vitro by M.Sssi. Then, the methylated plasmids and mock-treated controls were transfected into BPH-1 cells. After 48 hours of incubation, cells were
harvested and luciferase was quantiﬁed. F: DNMT1 cDNA and mock plasmids were transfected into BPE cells. After 48 hours of incubation, cells were harvested for
immunoblot and methylation pull-down assay. G: DNMT1 cDNA and mock plasmids were transfected into BPE cells for 48 hours and then nuclear extracts were subjected
to chromatin immunoprecipitation assay using a DNMT1 antibody or IgG. All experiments were repeated independently at least three times with similar results. 5-AZC,
aza-20-deoxycytidine; BPE, benign prostate epithelial; DMSO, dimethyl sulfoxide; M-CpG, methylation-CpG; SAM, S-Adenosyl methionine.
Ge et al(Figure 2D), further substantiating the role of DNMT1 and not
DNMT3 in regulating SRD5A2.
We next asked whether in vitro methylation of the
SRD5A2 promoter could repress gene expression of SRD5A2.
We methylated human SRD5A2-luc promoter constructs
in vitro using M.Sssi enzyme, a CpG methyltransferase
enzyme that methylates all cytosine residues (C5) within the
double-stranded dinucleotide recognition sequence CG. We
found that the activity of the methylase-modiﬁed SRD5A2
promoter was reduced signiﬁcantly after transfecting it into
BPH-1 cells (Figure 2E), providing direct evidence that
methylation of the SRD5A2 promoter region regulates its
gene expression. The introduction of exogenous DNMT1
cDNA into benign prostate epithelial cells further increased
SRD5A2 promoter methylation and reduced SRD5A2
expression as measured by the methylation pull-down assay
(Figure 2F). The ectopic overexpression of DNMT1 also
increased the binding of DNMT1 to the promoter region of
SRD5A2 (Figure 2G). These data suggest that DNMT1 plays
an important role in silencing SRD5A2 expression.
The Inﬂammatory Mediator TNF-a Contributes to
Silencing of SRD5A2 by Regulating DNMT1 Activity
Inﬂammatory changes have been associated with benign
prostatic hyperplasia, and alterations in various cytokine874levels have been associated with prostatic diseases.13,18 The
regulation of DNMT1 by cytokines has been well estab-
lished.19e21 Therefore, we asked whether the epigenetic
changes that regulate expression of SRD5A2 in benign
prostate tissue can be inﬂuenced by inﬂammation-mediated
cytokines. We therefore selected a group of prostate samples
from the SRD5A2 methylated and unmethylated groups
(Table 1). We measured the expression of different cyto-
kines using the MILLIPLEX MAP Human Cytokine/
Chemokine assay (Millipore, Billerica, MA) and found
relatively higher levels of TNF-a and IL-6 in the methylated
group, compared with the unmethylated group (Figure 3A).
We also measured the levels of TNFR1 and TNFR2 in BPH
samples and found that TNF-a and TNFR1 were up-
regulated, whereas no change was detected for TNFR2
protein expression levels between the methylated and
unmethylated SRD5A2 groups (Figure 3B and data not
shown).
To evaluate whether exogenous exposure of BPH-1 cells to
cytokines may alter the expression of DNA methylation-
regulating genes, cells were exposed to increasing doses of
TNF-a. We found that there was a dose-dependent increase in
expression of DNMT1 (Figure 3C). Conversely, we found that
suppression of TNFR1 with siRNA led to reduced levels of
DNMT1 and other well-deﬁned pathways known to be regu-
lated by TNF-a such as phospho-p65 and phospho-STAT3ajp.amjpathol.org - The American Journal of Pathology
Figure 3 Tumor necrosis factor alpha (TNF-a) contributes to silencing of
SRD5A2 by regulating DNMT1 activity. A: Levels of TNF-a (blue bars) and IL-6
(red bars) in benign prostatic hyperplasia (BPH) samples were measured by
the MILLIPLEX MAP Human Cytokine/Chemokine assay (Millipore). B:
Representative ﬁgures for protein expression of TNF-a and TNFR1 in BPH
samples by immunoblot. C: BPH-1 cells were treated with a different dosage
of TNF-a cytokines for 48 hours, and then cells were harvested for immu-
noblot analysis. D: BPH-1 cells were treated with TNFR siRNA for 48 hours,
and then cells were harvested for immunoblot analysis and DNMT1 activity
assay. The data represent means of average determinants  SEM. All ex-
periments were repeated independently at least three times with similar
results. **P < 0.01. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Table 2 Methylation of the SRD5A2 Promoter is Regulated by
DNMT1
Methylated
SRD5A2
Unmethylated
SRD5A2 Total
DNMT1 expression negative 2 (8%) 9 (36%) 11 (44%)
DNMT1 expression positive 10 (40%) 4 (16%) 14 (56%)
12 (48%) 13 (52%)
Twelve of 47 (25%) patients in the methylated group and 13 of 49 (25%)
patients in the unmethylated group were selected randomly. Statistical
analysis of the correlation between methylation and expression of DNMT1
(P Z 0.015). All tests were two-tailed, and P < 0.05 was considered
statistically signiﬁcant.
DNMT Reduces SRD5A2 in Adult Prostate(Figure 3D). The TNFR1 siRNA suppression of DNMT1
correlated well with enhanced expression of SRD5A2 protein
levels (Figure 3D), suggesting that inﬂammation-mediated
cytokines can play a signiﬁcant role in the regulation of
SRD5A2 levels in benign prostatic tissue.
Previously, it was suggested that p65, a potent proin-
ﬂammatory component of NF-kB, which is considered to be
a central mediator of immune and inﬂammatory response,22
promotes expression of DNMT1.23 Therefore, we deter-
mined whether TNF-a regulates DNMT1 through NF-kB
signaling in BPH samples. We found that suppression of
p65 down-regulated protein expression and activity of
DNMT1 (Figure 4A), whereas ectopic overexpression of
p65 up-regulated protein expression and activity of DNMT1
(Figure 4B). We also evaluated the global cellular methyl-
ation with suppression and ectopic expression of p65. We
measured the global methylation and found that suppression
of p65 down-regulated global cellular methylation levels,
and ectopic expression of p65 up-regulated the global
methylation (Figure 4C), suggesting that total cellular
methylation may be correlated closely with DNMT1 levels.
Next, we made a stable BPH-1 cell line with ectopically
expressed p65 (BPH-1/p65 cells) and then suppressed
TNFR1 using TNFR siRNA in BPH-1 and BPH-1/p65
cells. We found that overexpression of p65 compromised
siTNFR-mediated DNMT1 suppression (Figure 4, D and E),
which we found earlier (Figure 3D), suggesting that p65
functions downstream of TNFR1 in mediating DNMT1
expression. Finally, to evaluate the intimate role that
DNMT1 may have in regulating the SRD5A2 promoter, we
used a chromatin immunoprecipitation assay. We found
that DNMT1 strongly bound the SRD5A2 promoter region
(Figure 4F). Suppression of p65 using siRNA led to a
signiﬁcant reduction of binding between the SRD5A2
promoter region and DNMT1, whereas ectopic expression
of p65 led to enhancement of DNMT1 protein and
SRD5A2 promoter (Figure 4F). These results suggest that
cytokines including TNF-a and transcriptional factors such
as NF-kB (p65) contribute to silencing of SRD5A2 by
regulating DNMT1 activity. Therefore, NF-kB/p65 plays a
central role not only in increasing the expression of
DNMT1, but also in facilitating binding of DNMT1 to theThe American Journal of Pathology - ajp.amjpathol.orgSRD5A2 promoter region, leading to methylation and
suppression of the SRD5A2 gene.NF-kB Regulates DNMT1 Binding to SRD5A2 Indirectly
through an IL-6eDependent Pathway
In addition to TNF-a, we detected a signiﬁcant increase in
IL-6 in the human prostate samples known to have meth-
ylated SRD5A2 promoter regions (Figure 3A). We deter-
mined whether IL-6 also plays a role in the methylation of
the SRD5A2 promoter. We treated BPH-1 cells with 100 ng/
mL IL-6 cytokine for 48 hours and found, as expected, that
p-STAT3, a downstream molecule of IL-6, was increased
(Figure 5A). In addition to IL-6, the DNMT1 protein level
and DNMT1 activity also were increased (Figure 5, A and
B). To determine whether IL-6 signaling may affect
DNMT1 level and activity, we used an siRNA construct to
silence the IL-6 gene. In addition to the anticipated reduc-
tion in p-STAT3 levels, we found a signiﬁcant reduction in
DNMT1 protein level and activity in the BPH-1 cells with
suppressed IL-6 (Figure 5, C and D). These results show
that IL-6, another cytokine that is increased in SRD5A2
methylated human BPH samples (Figure 3A), regulates the
activity of DNMT1, which binds the promoter region of
SRD5A2 to regulate gene methylation and expression.
Both NF-kB and IL-6 play an important role in proin-
ﬂammatory states, in some IL-6 induces NF-kB activa-
tion,24 whereas in others IL-6 gene expression is activated875
Figure 4 NF-kB indirectly impacts SRD5A2 expression by regulating DNMT1 activity. A: BPH-1 cells were transfected with p65 siRNA for 48 hours, and
then cells were harvested for immunoblot analysis and DNMT1 activity assay. B: BPH-1 cells were transfected with p65 cDNA plasmids for 48 hours, and
then cells were harvested for immunoblot analysis and DNMT1 activity assay. C: Global methylation assay by the MethylFlash Methylated DNA quanti-
ﬁcation Kit (Epigentek). D: TNFR siRNA was transfected into BPH-1 or BPH-1/p65 cells for 48 hours, and then cells were harvested for immunoblot
analysis. E: DNMT1 activity assay. F: p65 siRNA or p65 cDNA plasmids were transfected into BPH-1 cells for 48 hours, and then nuclear extracts were
subjected to chromatin immunoprecipitation assay using a DNMT1 antibody or IgG. The data represent the means of average determinants  SEM. All
experiments were repeated independently at least three times with similar results. *P < 0.05, **P < 0.01. GAPDH, glyceraldehyde-3-phosphate
dehydrogenase.
Ge et althrough the NF-kB transcription factor.25 These differences
in signaling pathways may be owing to differences in tissue
types. To date, the interaction between NF-kB and IL-6, if
any, has not been studied in BPH. We found that both NF-
kB and IL-6 can modulate DNMT1 and ultimately affect
regulation of SRD5A2, therefore we wanted to determine
whether NF-kB and IL-6 worked in tandem or indepen-
dently to regulate DNMT1. To answer this question, we
suppressed IL-6 expression in BPH-1 cells and found that
p65 levels were not affected signiﬁcantly (Figure 5E). On the876other hand, suppression of p65 in BPH-1 cells suppressed the
expression of IL-6 (Figure 5F) and DNMT1 (Figure 4A),
whereas ectopic expression of p65 up-regulated IL-6/STAT3
signaling (Figure 5G). These results suggest that IL-6 is
downstream to NF-kB in the regulation of DNMT1 and
methylation of the SRD5A2 gene in BPH.
Because other investigators have shown that NF-kB can be
associated directly with the promoter region of DNMT1 to
regulate its transcription,23 we next asked whether NF-kB
could bypass IL-6 signaling and regulate DNMT1 directly inajp.amjpathol.org - The American Journal of Pathology
Figure 5 NF-kB regulates the methylation status of SRD5A2 indirectly through an IL-6 pathway. A: BPH-1 cells were treated with 100 ng/mL IL-6 for 24 hours
and then cells were harvested for immunoblot analysis. PBS-treated samples were used as control. B: DNMT1 activity assay. C: BPH-1 cells were transfected with IL-6
siRNA for 48 hours, and then cells were harvested for immunoblot analysis. D: DNMT1 activity assay. E: BPH-1 cells were transfected with IL-6 siRNA for 48 hours, and
then cells were harvested for immunoblot analysis. F: BPH-1 cells were transfected with p65 siRNA for 48 hours, and then cells were harvested for immunoblot
analysis.G:BPH-1 cells were transfected with p65 cDNA plasmids for 48 hours, and then cells were harvested for immunoblot analysis.H:BPH-1 cells were transfected
with p65 siRNA or a combination of p65 siRNA and IL-6 cDNA plasmids for 48 hours, respectively, and then cells were harvested for immunoblot analysis. I: DNMT1
activity assay. J: p65 siRNA or combination of p65 siRNA and IL-6 cDNA plasmids were transfected into BPH-1 cells for 48 hours, respectively, and then nuclear
extracts were subjected to a chromatin immunoprecipitation assay using a DNMT1 antibody or IgG. The data represent the means of average determinants SEM. All
experiments were repeated independently at least three times with similar results. *P < 0.05. PBS, phosphate-buffered saline.
DNMT Reduces SRD5A2 in Adult ProstateBPH tissues. By suppressing p65 we found signiﬁcant down-
regulation of IL-6, p-STAT3, and DNMT1, in addition to a
signiﬁcant reduction in DNMT1 activity. However, simulta-
neous ectopic expression of IL-6 in p65-suppressed cells led
to re-expression of DNMT1 protein levels (Figure 5H) and
resurgence of DNMT1 activity (Figure 5I). In addition, we
found that suppression of p65 reduced binding of the
DNMT1 protein to the SRD5A2 promoter, whereas simulta-
neous ectopic overexpression of IL-6 in suppressed si-p65/
BPH-1 cells increased the binding of DNMT1 to theThe American Journal of Pathology - ajp.amjpathol.orgSRD5A2 promoter (Figure 5J). These results show that
NF-kB/p65 regulates DNMT1 binding to the SRD5A2 pro-
moter via an IL-6edependent pathway.
Aging Leads to Reduced Expression of SRD5A2
We have shown that cytokines such as TNF-a, NF-kB, and
IL-6 contribute to DNMT1-mediated hypermethylation of
the SRD5A2 promoter and reduced expression of SRD5A2.
Moreover, age-related inﬂammation has been associated877
Figure 6 Aging is associated with a reduced expression of SRD5A2. A: Deﬁnition of middle- and old-age group. Levels of TNF-a and IL-6 in benign prostatic
hyperplasia samplesweremeasuredby theMILLIPLEXMAPHumanCytokine/Chemokineassay(Millipore, lowerpanel).B:Thebenignprostatic tissueswereharvested from
C57BL/6 mice of different ages (3 months, 6 months, and 12 months; n Z 6). Representative ﬁgures for protein expression of DNMT1, DNMT3a, and DNMT3b by
immunoblot assay. C: Representative ﬁgures for methylation status of the SRD5A2 promoter by a methylation pull-down assay. D: DNMT1 activity assay. E: Global
methylation assay by MethylFlash Methylated DNA quantiﬁcation Kit (Epigentek). F: Levels of TNF-a and IL-6 in murine prostates were measured by the MILLIPLEX MAP
Human Cytokine/Chemokine assay. G: Representative ﬁgures for protein expression in murine prostates by immunoblot. H: BPEs were treated with 100 ng/mL LPS or a
combination of LPS and 1 mg/mL TNF-a inhibitor for 48 hours, and then cells were harvested for immunoblot analysis. The data represent means of the average
determinants SEM. All experiments were repeated independently at least three times with similar results. *P< 0.05, **P< 0.01. BPE, benign prostate epithelial cell.
Ge et alwith many benign and malignant disease states.26 To
determine whether the level of prostatic inﬂammation also is
associated with increasing age, we divided our patient
cohort into quartiles and compared the lowest quartile878(younger men, age < 65 years) against the highest quartile
(older men, age > 77 years) (Figure 6A). We analyzed the
TNF-a and IL-6 levels in the surgically treated BPH sam-
ples and found that prostatic levels of TNF-a and IL-6 wereajp.amjpathol.org - The American Journal of Pathology
Table 3 Promoter Status of SRD5A2 by Age Group
Age
Total
(n Z 96)
Methylated
(n Z 47)
Unmethylated
(n Z 49) P value
Range (years) 52e91 52e91 53e87 0.017
Mean (years) 70.8 73.0 68.7
SD 8.72 9.1 7.7
Table 4 Protein Expression of SRD5A2 by Age Group
Age
Total
(n Z 96)
Positive
expression
(n Z 51)
Negative
expression
(n Z 45) P value
Range (years) 52e91 52e86 53e91 0.0397
Mean (years) 70.8 69.1 72.8
SD 8.72 8.6 8.6
DNMT Reduces SRD5A2 in Adult Prostatesigniﬁcantly higher in older men compared with younger
men (P < 0.05) (Figure 6A).
We next asked whether increasing age is associated with
changes in methylation status of the SRD5A2 promoter and
protein expression of SRD5A2. We found that the mean
age for the patients’ prostate samples with methylated
SRD5A2 was 73 years old (SD, 9.1 years), whereas the
mean age for those with unmethylated SRD5A2 was 68.7
years old (SD, 7.7 years) (P < 0.05) (Table 3). By using
SRD5A2 protein expression as a marker, we found that the
mean age in prostate samples that expressed SRD5A2 was
69.1 years (SD, 8.6 years), and the mean age in prostate
samples that did not express SRD5A2 protein was 72.8
years (SD, 8.6 years) (P < 0.05) (Table 4). Moreover, the
quartile analysis of the 96 BPH samples showed that in the
group of younger men (n Z 24; average age, 59.3 years;
SD, 4.5 years), 9 of 24 (38%) patients had a methylated
SRD5A2 promoter, whereas in the group of older men
(n Z 23; average age, 82 years; SD, 4 years) 16 of 23
(70%) patients showed methylation of the SRD5A2 pro-
moter (P < 0.05, Fisher exact test) (Figure 6A and
Table 5). These results from our patient cohort suggest that
increasing age is associated strongly with increased
methylation of the SRD5A2 promoter region and reduced
SRD5A2 protein expression.
To further investigate the association between age and
methylation status of SRD5A2, we harvested normal pros-
tatic tissues from wild-type mice of different ages
(3, 6, and 12 months; n Z 6 per group) and found that
expression of SRD5A2, DNMT1, DNMT3a, and DNMT3b
were not changed signiﬁcantly in mice at the ages of 3 and 6
months. However, two of six mice at the age of 12 months
had decreased levels of SRD5A2, with concomitantly
increased DNMT1 levels, without a signiﬁcant change in
DNMT3a and DNMT3b levels (Figure 6B), consistent with
ﬁndings in the patient cohort (Figure 2). Methylation of the
SRD5A2 promoter was increased as assessed by methylation
pull-down assay (Figure 6C). DNMT1 activity was low at
the ages of 3 and 6 months, and higher at the age of 12
months (Figure 6D). The global methylation level was
associated with the level of DNMT1 activity (Figure 6E).
Moreover, we also measured prostatic levels of cytokines
including TNF-a and IL-6 in these wild-type mice of
varying ages, and found that the levels of TNF-a and IL-6
were higher in mice at 12 months, compared with cyto-
kine levels at 3 and 6 months of age (Figure 6F). We also
measured the prostatic levels of TNFR1, p65/NF-kB, IL-6,
STAT3, and DNMT1 and found that in older mice prostaticThe American Journal of Pathology - ajp.amjpathol.orginﬂammatory mediators were increased with concomitantly
increased expression of DNMT1 and suppression of
SRD5A2 (Figure 6G), ﬁndings similar to those in BPH-1
cell lines and human prostate samples.
Next, to test whether artiﬁcial induction of inﬂammatory
mediators may affect the expression of SRD5A2, primary
benign prostatic epithelial cells were exposed to LPS as an
artiﬁcial inducer of inﬂammatory mediators. LPS (100 ng/mL,
48 hours) induced signiﬁcant up-regulation of inﬂammatory
mediators, increased expression of DNMT1, and concomitant
down-regulation of SRD5A2. The increase in LPS-induced
inﬂammatory mediators and the decrease in SRD5A2
levels were abrogated when 1 mg/mL TNF-a inhibitor
(48 hours) was used in conjunction with LPS, suggesting
that inﬂammatory mediators can regulate the expression
of DNA methylation modiﬁers, DNMT1, and SRD5A2
(Figure 6H). Combined, these results show that increased
expression of DMNT1, methylation of the SRD5A2 pro-
moter, and reduced expression of SRD5A2 protein are
associated strongly with increased inﬂammatory media-
tors with aging.
Discussion
BPH, a benign enlargement of the prostate in aging men, leads
to obstruction of urinary outﬂow, causing obstructive lower
urinary tract symptoms. It is one of the most common men’s
health-related issues in the aging population worldwide.27
Approximately 40% of men in their ﬁfties and 90% of men in
their eighties have histologic evidence of BPH.28 For manage-
ment of obstructive lowerurinary tract symptoms resulting from
BPH, lifestyle modiﬁcations are advised initially, followed by
medical interventions. 5-a reductase inhibitors such as ﬁ-
nasteride and dutasteride are two of the most commonly
prescribed medications for the management of obstructive
lower urinary tract symptoms resulting from BPH.29e31
Targeted inhibition of SRD5A2 by ﬁnasteride leads to a
reduction of total prostate volume size and improvement of
obstructive lower urinary tract symptoms. However,
approximately 30% of patients do not respond to ﬁnasteride
treatment.30,32 Although once believed to be expressed
ubiquitously in all normal human prostates, we have shown
that 30% of benign human prostate samples do not express
the SRD5A2 protein, and methylation of the SRD5A2 pro-
moter region may account for low or absent expression of
SRD5A2 in some human adult prostate tissues.6879
Figure 7 Schematic diagrams of cytokine-mediated activation of DNMT1
and silencing of SRD5A2 in benign prostatic tissues. With increasing age,
inﬂammatory mediators, TNF-a, NF-kB, and IL-6 lead to up-regulation of
DNMT1 and methylation of the SRD5A2 promoter and suppression of gene
expression. NF-kB regulates DNMT1 through an IL-6edependent pathway.
Table 5 Deﬁnition of Middle- and Old-Age Group and Quartile
Analysis of Promoter Status of SRD5A2 by the Two Age Groups
Promoter of
SRD5A2
Middle age
(n Z 24)
Old age
(n Z 23)
Methylated 9 16
Unmethylated* 15 7
All tests were two-tailed, and P < 0.05 was considered statistically
signiﬁcant.
*P Z 0.04.
Ge et alHere, we ﬁrst evaluated 96 human prostate samples for
SRD5A2 protein expression by immunohistochemistry and
for methylation status of the promoter by methylation pull-
down assay. We found that 36.5% of patients did not express
the SRD5A2 protein with an associated concomitant hyper-
methylation of the SRD5A2 promoter, suggesting that
methylation of the SRD5A2 promoter suppressed gene and
protein expression of SRD5A2. However, in approximately
10% of samples, we identiﬁed discordance in which
SRD5A2 protein was not detected despite a lack of promoter
methylation, suggesting that other mechanisms besides pro-
moter methylation may suppress SRD5A2 expression. For
example, histone deacetylation, nucleosome occupancy, or
gene modiﬁcations all can account for other mechanisms that
may modulate the expression of SRD5A2.33
We next asked which family of proteins may regulate
methylation of the SRD5A2 promoter. We measured
DNMT1, DNMT3a, and DNMT3b levels and found that
methylation of the SRD5A2 promoter was correlated closely
with DNMT1 levels but not DNMT3a, DNMT3b or G9a
(Figure 2, AeE, and data not shown). Although methylation
of tumor-suppressor genes and their role in initiation and
progression in neoplasia is well studied, the idea that epige-
netic changes may be involved in benign disease models is
less appreciated.34 Because the prostate gland is the only
solid organ that grows during adulthood, we postulated that
epigenetic modiﬁcations may play an important role in
mediating expression of SRD5A2 in a manner similar to that
observed in tumor growth.35 In benign prostate diseases, to
our knowledge, epigenetic changes in regulating SRD5A2, a
gene that is essential for the development and growth of the
prostate gland, have never been shown. In this study, we
show for the ﬁrst time that epigenetic modiﬁcations of
SRD5A2 exist and are regulated by DNMT1.
Inﬂammation has been associated with the development of
obstructive BPH in clinical and pathologic studies.13,36e38
Moreover, the methylation status of promoter CpG islands
and global DNA hypermethylation are correlated with
expression levels of various cytokines.39,40 Therefore, we
measured cytokine levels in BPH samples obtained from
transurethral resections of the prostate and found that TNF-a,
NF-kB, and IL-6 regulate DNMT1, thus indirectly impacting
5-a reductase protein expression (Figures 3, 4, and 5).
Correlations between inﬂammation and aging have been
studied extensively.41,42 Therefore, we determined whether880increasing age may affect methylation status or protein
expression of SRD5A2. We found that increasing age was
correlated strongly with methylation of SRD5A2 and reduced
expression of the protein (Tables 3, 4, and 5). To further test
the hypothesis that increasing age may promote inﬂammatory
mediators and methylation of SRD5A2 as well as reduced
protein expression, we evaluated the prostates of wild-type
C57BL/6 mice at various ages. Similar to our ﬁndings in
the human cohort, we found that older mice at 12 months of
age had relatively lower levels of SRD5A2 with concomitant
increases in methylation status and cytokine levels (Figure 6).
Similarly, artiﬁcial induction of cytokines by LPS in primary
prostate epithelial cells led to similar increases in DNMT1
expression with a concomitant reduction in SRD5A2 levels.
Collectively, the in vitro, animal, and human ﬁndings showed
that epigenetic factors associated with aging and inﬂamma-
tion modulate the expression of SRD5A2, which plays an
important role in prostatic growth and the development of
bladder outlet obstruction resulting from BPH.
Our study lays the groundwork to develop strategies for
personalized care for the management of BPH. It is possible
that patients lacking SRD5A2 protein expression may account
for the majority of patients who are resistant to the therapeutic
effects of ﬁnasteride. Therefore, alternative strategies may
need to be considered in this subset of patients for the treatment
of bladder outlet obstruction secondary to an enlarged prostate.
In addition, patients with absent SRD5A2 expression may
have different prostatic growth rates during adulthood, which
could account for the broad range of prostatic sizes observed in
adult men. To evaluate the mechanism of resistance to ﬁnas-
teride and variable prostatic growth patterns, prospectively
evaluated cohorts over several years are required, an effort that
is part of our current ongoing research program.
In conclusion, our study shows that the expression of
SRD5A2, a key regulator of prostatic growth during adult-
hood, is variable and not expressed ubiquitously, as has
been assumed for many years. We show that the expressionajp.amjpathol.org - The American Journal of Pathology
DNMT Reduces SRD5A2 in Adult Prostateof SRD5A2 is mediated by methylation. Proinﬂammatory
mediators affect DNMT1, which in turn regulate the
methylation and expression of SRD5A2 (Figure 7). Evalu-
ating the epigenetic factors that regulate the expression of
prostatic SRD5A2 has signiﬁcant clinical implications.
First, it may explain the differential growth pattern of the
benign prostate gland during adulthood, and, second,
epigenetic changes associated with SRD5A2 may be
explored for providing personalized care in the management
of patients with benign and malignant prostatic diseases.Acknowledgments
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